Tesofensine
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Tesofensine?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Tesofensine (NS2330) is a serotonin–noradrenaline–dopamine reuptake inhibitor from the phenyltropane family of drugs, which is being developed for the treatment of obesity.[1] Tesofensine was originally developed by a Danish biotechnology company, NeuroSearch, who transferred the rights to Saniona in 2014.[2]
Quick Facts Clinical data, Pregnancycategory ...
Clinical data | |
---|---|
Pregnancy category |
|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 90% |
Metabolism | 15–20% renal; hepatic: CYP3A4 |
Elimination half-life | 220 hours |
Excretion | Not applicable |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H23Cl2NO |
Molar mass | 328.28 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Close
As of 2019, tesofensine has been discontinued for the treatment of Alzheimer's and Parkinson's disease but is in phase III clinical trial for obesity.[3]